Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 2 study titled ‘A ...

In late May, a patient died after receiving Rocket Pharmaceuticals' investigational gene therapy for Danon disease, spurring ...

Rocket Pharmaceuticals' shares rallied ahead of the opening bell after the Food and Drug Administration lifted its clinical hold on the biotechnology company's Phase 2 trial of its RP-A501 treatment ...

Celldex Therapeutics Inc. will not advance barzolvolimab (CDX-0159, barzo) in eosinophilic esophagitis (EoE) after taking a ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. Click here to read why SLS stock ...

The MTA board approved an approximately $2 billion tunnel boring contract for the Second Avenue Subway line expansion in ...

The participants will receive either 100 mg of verekitug every 12 weeks, 400 mg every 24 weeks, or a placebo, throughout 60 ...

Alto Neuroscience Inc. (NYSE: ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto ...